Biodesix
Business Services · Colorado, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
919 W Dillon Rd, Louisville, Colorado, 8...Phone Number
(303) 417-0500Website
www.biodesix.comRevenue
$102.9 MillionStock Symbol
BDSXIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
3
4
1
1
2
2
About Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions.Explore more
Biodesix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biodesix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Biodesix is spiking on competitors!
Product Launch: Get notified when Biodesix launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Biodesix had a recent Job posting/layoffs
Earning: See what the market has to say on Biodesix recently announced quarterly report
Funding: Get notified immidiatlly once Biodesix has new funding data
Congratulate Masked Content for being promoted to Masked Content at Biodesix
Biodesix, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Biodesix has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Biodesix
Compare insights from companies similar to Biodesix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$60.1M
51-200
Private
$82M
2006
DV
Daniel VummagoniCorporate Development Senior VP & Chief Financial Officer
Company Profile Activity
Activity Insights
Biodesix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Biodesix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Biodesix.
Biodesix financials insights
Gather financial insights about Biodesix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series C
$7.1M
2011
Series D
$20M
2015
Series E
$38M
2016
Series F
$22M
2018
Debt
$23M
2020
Debt
$2M
Stock Offering
$72M
2022
Stock Offering
$16.3M
Stock Offering
$50M
Biodesix Tech Stack
A closer look at the technologies used by Biodesix
See more technologies
Most Recent Scoops
Person-Based
Corporate Strategy
Person-Based
Earnings, Forecasting, Finance
Person-Based
Medical Research
Person-Based
Award, Sales
Person-Based
Medical Research
Biodesix News & Media
Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript
Biodesix, Inc. (BDSX) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsScott Hutton - President, CEO & DirectorRobin Cowie - CFO,...Biodesix Q2 Earnings Call Highlights
Biodesix (NASDAQ:BDSX) reported second-quarter 2026 revenue growth of 34% year over year, supported by increased diagnostic test volumes, higher average revenue per test and continued expansion of its commercial organization. Total revenue was $26.9 million for the quarter, while diagnostic testingBiodesix Announces Second Quarter 2026 Results and Highlights
Delivered $26.9 million in revenue, representing 34% growth in Q2 2026;Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity’s 46th Annual Growth Conference, which will be held from August 11-12, 2026.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biodesix
Sign Up For FreeTo access detailed company insights
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathwa... Read More
